Citations 1
Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.
Voorhees, Peter M. , Goldschmidt, Hartmut , Bandekar, Rajesh, Kuppens, Steven, Qi, Ming , Rajkumar, S. Vincent , Baker, Ross , Neff, Tobias , Dimopoulos, Meletios Α.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS8062-TPS8062
